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JONATHAN TODRES AND PAMELA L. MARCOGLIESE*
In recent years, global health issues-including the continued spread of AIDS, outbreaks
of severe acute respiratory syndrome (SARS) and avian influenza, as well as the threat of
bioterrorism-have garnered increased attention by all countries. In 2004, this trend
spurred efforts by the international community to further develop effective response systems
to these and many other global health issues.
Perhaps as much as any other area covered by international law, health issues demand a
coordinated effort by international, national, and local institutions.' Outbreaks of infectious
disease that have the potential to spread rapidly across borders-such as SARS-have
forced governments and health care professionals to rethink current response methods.
Increasingly, countries are working to develop an international health law and policy frame-
work that enables them to coordinate their responses and effectively address future public
health crises.
International health, however, is not limited to public health emergencies. Over the past
several years, it also has concentrated on a range of other issues, including developments
in biomedical science (including stem cell research), pharmaceuticals and trade law issues,
medical experimentation involving human subjects, and the intersection between health
and human rights. The year 2004 witnessed a number of significant developments in in-
ternational health law.
I. HiIV and AIDS
In 2004, the spread of HIV/AIDS and efforts to control the disease continued to be
among the most important international health issues. Numerous concerns arise in the
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occurred from January 1, 2004 through December 31, 2004. As in prior years, space limitations for this article
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1. See generally Allyn L. Taylor, Shifting Norms in International Healtb Law, 98 Am. Soc'Y INT'L L. PROC. 22
(2004) ("There is widespread recognition that national and international health are increasingly intertwined
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context of HIV and AIDS, including the adequacy of funding for HI-V/AIDS programs,
research and development, concerns over access to care (including the affordability and
availability of antiretroviral therapies), discrimination against individuals living with HIV/
AIDS, and the impact on children orphaned as a result of AIDS. Currently, approximately
forty million people are living with HIV or AIDS.' In the past year, nearly five million
people contracted the HTV virus, and over three million people died as a result of AIDS.'
Sub-Saharan Africa, home to over 60 percent of people living with IIV,,4 continues to be
the hardest hit region, although rates of infection are increasing in every region of the
world, most dramatically in East Asia, Eastern Europe, and Central Asia.' In addition,
women and girls are increasingly affected by HTV/AIDS. 6
Funding for HIV/AIDS programs received a boost in February 2004, as the United States
announced its fifteen billion dollar, five-year global HIV/AIDS strategy.7 This initiative,
known as the President's Emergency Plan for AIDS Relief (PEPFAR), has set goals of (1)
treating two million HTV-positive people with antiretroviral therapy, (2) providing care for
ten million people infected with and affected by HIV/AIDS, including children and or-
phans, and (3) preventing seven million new infections.' While this new initiative is a wel-
come development in U.S. policy, there are a number of concerns, including the following:
PEPFAR's bilateral structure provides little funding for the Global Fund to Fight AIDS,
Tuberculosis, and Malaria, which currently is the accepted multilateral funding structure;
PEPFAR does not sufficiently ensure the participation of local constituencies; funding for
PEPFAR back-loads, rather than front-loads, resources; and PEPFAR may not adequately
account for human rights issues that affect persons living with HIV/AIDS.9 Numerous other
countries and private sector entities also contributed significantly to the funding of HIV/
AIDS-related programs.
Throughout 2004, access to pharmaceuticals, in particular AIDS-related drugs, remained
a primary focal point of debate. The World Health Organization (WHO), the Joint United
Nations Program on HWV/AIDS (UNAIDS), and partner governments and agencies con-
tinued efforts to reach the announced targets of the "3 by 5" initiative.10 This initiative was
launched in December 2003, to provide three million HIV-infected individuals, or half of
all people in need, with treatment by the end of 2005." By the end of 2004, 700,000 people
living with AIDS in developing countries were receiving antiretroviral treatment as a result
of these efforts, an increase of approximately 75 percent in the total number of treated
2. See Joint United Nations Programme on HIV/AIDS & World Health Organization, AIDS Epidemic
Update: December 2004, available at http://www.unaids.org/wad2004/EPl_1204-pdLen/EpiUpdateO4-en.pdf.
3. Id. at 2.
4. Id. at 7.
5. Id. at 2.
6. Id. at 4. While women make up just under 50% of the current global HIV-positive population, 57% of
HIV-positive individuals in Sub-Saharan Africa are women, and 76% of young people (15-24year-olds) in that
region living with HIV are female. This development raises questions concerning whether programs and ser-
vices are adequately reaching women and girls.
7. Leonard S. Rubenstein & Eric A. Friedman, Human Rigbts and the President's AIDS Initiative, HUMAN
RIGHTS MAc., Fall 2004, at 4, available at http://www.abanet.org/irr/hr/fall04/initiative.htm.
8. Id. at 4.
9. Id. at 4-5.
10. See World Health Organization, 700,000 People Living With AIDS in Developing Countries Now Receiving
Treatment (Jan. 26, 2005), available at http://www.who.int/mediacentre/news/releases/2005/prO7/en/index.htnl.
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individuals from just one year ago.'2 Access to antiretroviral drugs remains an issue in the
United States as well. In February 2004, the AIDS Healthcare Foundation, a California-
based AIDS advocacy group, filed suit against Abbott Laboratories, claiming that a recent
400 percent increase in the price of an essential AIDS drug violated antitrust laws and
constituted a restraint of trade. 3 The case could have significant implications for drug
pricing and access to pharmaceuticals.
Individuals with HTV/AIDS and their family members still confront discrimination in all
sectors of society, ranging from discrimination in access to healthcare and other social
services to workplace discrimination. In 2004, Non-governmental organizations and inter-
national agencies continued to pressure governments to better protect HTV/AIDS individ-
uals from such discrimination and human rights abuses. As a result, a number of govern-
ments adopted or strengthened laws prohibiting discrimination against people with HIV/
AIDS. For example, Indonesia adopted legislation mandating equal opportunity in the
workplace for individuals living with HIV/AIDS and prohibiting employers from perform-
ing HIV tests as part of hiring requirements or routine medical exams.14 Similarly, Tanzania
enacted new labor laws that included a prohibition on "direct or indirect discrimination in
any employment policy" on the grounds of HPV/AIDS."
Finally, in 2004, there was growing recognition of the impact of H1V/AIDS on the family
members of those living with HIV/AIDS, especially children orphaned as a result of AIDS.
Currently, an estimated fourteen million children are orphans because of AIDS. 16 Research
has found that children who are perceived to be HIV-positive, due to the death of a parent
known to have AIDS, are stigmatized and isolated by their communities.' They suffer
discrimination in access to schools and health care facilities, and are at increased risk of
exploitation through child labor and forced prostitution.'8 Thus, even if these children are
not HIV-positive, their health and well-being (and even their lives) are threatened, and
additional efforts are needed to protect and provide for these children.
H. Infectious Disease Control
A. INTERNATIONAL HEALTH REGULATIONS
The primary international legal framework for infectious disease control is the Interna-
tional Health Regulations (IHR), originally promulgated in 1951." The IHR (1) provide
12. Id.
13. See AIDS Healthcare Found. v. Abbott Labs., No. CV04-919 (RCx), (C.D. Cal., W. Div. filed Feb. 10,
2004); See also Advocacy Group Files Suit on AIDS Drug Price Hike: AIDS Healthcare Found. v. Abbott Lab., 11
No. 11 ANDREWS HEALTH L. LITIG. REP. 14 (2004).
14. Decree of the Minister of Manpower and Transmigration of Republic of Indonesia on HIV/AIDS Pre-
vention and Control in the Workplace, (Number: Kep. 68/MEN/2004) (Adopted Apr. 28, 2004), available at
htp://www.unaids.org/html/pub/topics/partnership-menus/indonesia-hiv-workplace en.-pdf.pdf.
15. Employment and Labour Relations Act (2004) (Tanz.), availabkatwww.io.org/public/engish/employment/
gems/eeo/law/tanzania/elra.htm.
16. Mark Katz, HIV/AIDS: Twenty-two Years and Counting: 1here are We?, 25 WHITrIER L. REv. 233 (2003).
17. Ann Strode & Kitty Barrett Grant, The Role of Stigma and Discrimination in Increasing the Vulnerability of
Children and Youth Infected with and Affected by HIV/AIDS, SAVE THE CHILDREN (UK), at 15 (Nov. 2001), available
at http://www.eldis.org/static/DOC15342.hun.
18. Id.
19. World Health Organization, Current International Health Regulations, available at www.who.int/csr/ihr/
current/en/print.html (last visited May 18, 2005). The IHRs apply to all 192 WHO Member States.
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for notification to the WHO of cases of certain contagious diseases and coordination of
any international response to covered outbreaks of such diseases; (2) establish health-related
rules for international trade and travel; (3) outline procedures for governmental health
agencies, such as public health controls related to goods at airports, ports, and other entry
points; and (4) establish requirements for health and vaccination certificates for interna-
tional travelers. 20 The IHR, last revised in 1969, were limited to three "notifiable dis-
eases"-cholera, plague, and yellow fever.2 In light of recent outbreaks of SARS and avian
influenza, the rapid spread of these diseases across borders, as well as potential outbreaks
of small pox and other highly contagious diseases, governments and international health
experts called for a broadening of the reach of the IHR. In November 2004, governments
met to negotiate revisions to the IHR, based on a proposal by the WHO.2 The aim of the
new IHR are to "prevent, protect against, control, and provide a public health response to
the international spread of disease in ways that are commensurate with and restricted to
public health risks, and which avoid unnecessary interference with international traffic and
trade."12 The new IHR, which also seek to establish more clearly the role for the WHO in
leading and coordinating the response of various countries to outbreaks of infectious dis-
eases, were adopted at the World Health Assembly meeting in May 2005.14
B. REGIoNAL EFFORTS
In addition to the revision of the IHR, there are also a number of ongoing regional
efforts aimed at addressing infectious diseases. In April 2004, the European Union (EU)
established an EU Centre for Disease Prevention and Control,2 that is expected to become
operational by May 2005.16 The Centre was created in order to coordinate regional efforts
dealing with communicable diseases. The EU regulation establishing the Centre outlines
procedures for disease surveillance, scientific opinions, operation of an early warning and
response system, scientific and technical assistance, identification of emerging health threats,
and data collection and analysis.27 Despite concerns about its limited funding, insufficient
staffing and inadequate availability of facilities, s the Centre is "seen by the European Com-
mission as having a key role to play in delivering the [EU]'s public health agenda in the
face of infectious diseases like [SARS], bird flu, and HIV/AIDS."29 Additionally, the Asso-
ciation of South Asian Nations (ASEAN) initiated a Southeast Asia regional program to
20. Id.
21. World Health Organization, Review and Approval of Proposed Amendments to the International Health Reg-
ulations: Explanatoy Notes, A/IHR/IGWG/4 (Oct. 7, 2004), at para. 3, available at http://www.who.int/gb/ghs/
pdf/A_IHRIGWG_4-en.pdf.
22. Id.
23. World Health Organization, Revision of the International Health Regulations, WHA58.3 (May 23, 2005),
available at http://www.who.int/gb/ebwha/pdf-files/WHA58/WHA58-3-en.pdf.
24. Id.
25. European Parliament & Council of the European Union Regulation 851/2004 of 21 April 2004 Estab-
lishing a European Centre for Disease Prevention and Control, 2004 Oj. (L 142) 1-11.
26. Stephen Pincock, Euro CDC Gathers Steam (Sept. 29, 2004), availableat http://biomedcentral.com/news/
20040929/01 [hereinafter Euro CDC].
27. Id.
28. Stephen Pincock, ECDC Director Named (Dec. 22, 2004), available at http://www.biomedcentral.com/
news/20041222/01 [hereinafter ECDC Director]; See also Euro CDC, supra note 26.
29. ECDC Director, supra note 28.
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confront avian influenza with Thailand, Indonesia, Malaysia, Singapore, and the Philippines
each responsible for coordinating specific measures to address the disease2 °
I. Pharmaceuticals
A. AccEss TO AFFORDABLE MEDICINES
With the increasing cost of pharmaceuticals, access to affordable medicines is no longer
an issue that solely affects developing countries. Rather, the governments of all nations must
address their ability to provide affordable drugs to their citizens. Access to affordable med-
icines in the United States figured prominently as an issue for debate in the 2004 presi-
dential election campaign." At the federal level, two reports ordered by the U.S. Congress
were released by the Bush Administration in December 2004.32 In advising against the
importation of pharmaceuticals from abroad, a view not unanimously endorsed, these re-
ports take the position that, as a preliminary matter, the U.S. Food and Drug Administration
(FDA) is unable to ensure the safety of pharmaceuticals purchased by individual consumers
from other countries." The reports further suggest that a federal system of bulk importation
would facilitate oversight procedures, particularly if all drugs are imported from a single
country (namely Canada)14 Such a policy, however, would ultimately be disadvantageous
to consumers because the decrease in profits for U.S. drug manufacturers would result in
a corresponding reduction in spending on future research and development."
Despite the FDA's objection to the importation of pharmaceuticals, several states, in-
cluding Illinois, Wisconsin, Missouri, and Kansas, are allowing their citizens to obtain
prescription drugs from Canada at more affordable prices.3 6 However, because the Canadian
government is considering putting an end to this arrangement, these states are increasingly
turning to countries in Europe, and possibly Australia and New Zealand, to provide their
residents with affordable medicines."
On a more global scale, the trade-related aspects of Intellectual Property Rights (TRIPS)
Agreement, created under the auspices of the World Trade Organization in 1995, has had
a significant impact on access to medications." For example, on December 31, 2004, the
five-year transition period accorded to India, the world's largest producer of generic phar-
maceuticals, came to an end. 9 As a result, the production of generic drugs in India must
now comply fully with the TRIPS Agreement and, in particular, with the requirement that
30. Asean Action Plan to Fight Bird Flu, THE STRAITS TIMES (Sing.) (Dec. 22, 2004) (on file with author).
31. President George W. Bush and SenatorJohn Kerry Second 2004 Presidential Debate Transcript, available
at http://64.233.161.104/search?q=cache:3DQPLWGpBf8J:www.4president.org/debates/2004Debate2.htm+
2004 + presidential + debates + pharmaceuticals&hl = en (last visited July 23, 2005).




36. Associated Press, Fearing End to Canada Drugs, States Now Look to Europe (Jan. 14, 2005), available at
http://www.netdr.com/healthnews/canada -drugs.htm.
37. Id.
38. Bonita de Boer, TRIPS, AIDS and Generic Drugs, available at http://www.avert.org/generic.htm (last
modified Feb. 22, 2005).
39. Id.
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India obtain a compulsory license to manufacture all drugs patented since 1995. 40 Not only
is the compulsory licensing process demanding, but it can trigger adverse consequences
because of the risk that large pharmaceutical companies will be reluctant to invest in coun-
tries that produce generic alternatives to their drugs.41 Furthermore, countries that are
unable to produce their own affordable drugs must import them from other countries under
specific circumstances and typically at costs that may exceed their available health care
funding.42 In light of this international legal framework, India's compliance with the pro-
visions of the TRIPS Agreement likely will hinder access to affordable pharmaceuticals
from India in the most resource-constrained countries, further contributing to the public
health crises facing countries most in need of affordable drugs. 41 Balancing intellectual
property considerations with the need to ensure access to medicines will continue to be a
major challenge in the foreseeable future.
B. RESEARCH AND DEVELOPMENT OF PHARMACEUTICALS
In response to the increasing cost of pharmaceuiticals and the mounting difficulties of
access to these drugs, alternative methods of financing research and development have
emerged. For example, the Bill and Melinda Gates Foundation provides substantial funding
for medical research.- This includes a $168 million contribution for the research and de-
velopment of a treatment for malaria. 41 This donation is an important example of a public/
private initiative.- Similarly, in October 2004, as a result of a collaborative effort on the
part of the Mozambican Ministry of Public Health and GlaxoSmithKline, researchers an-
nounced that, for the first time, a vaccine against malaria had proven effective in saving
children from infection or death.47 The vaccine was found to prevent infection in only 30
percent of cases and prevent life-threatening illness in 58 percent of cases. 41 Although these
results are relatively low, considering that malaria kills over one million people a year, most
of whom are children, this vaccine offers the hope of saving thousands of lives.
In September 2004, the University of California at Berkeley and the government of Sa-
moa entered into an agreement that requires both parties to share equally in royalties
derived from the sale of an anti-AIDS drug developed by using a Samoan native mamala
tree.49 The agreement also mandates that, in the event of any licensing of the drug to a
pharmaceutical company, the drug must be made available in the developing world either
40. Id. Under TRIPS, generic versions of all drugs patented prior to 1995 may continue to be produced as
before in India, but all drugs patented-after this date require a compulsory license for production.
41. Id.
42. Id.
43. DFIC Health Systems Resource Centre, Access to Medicines in Under-served Markets, 12, 14 (Sept. 2004),
available at http://www.dfid.gov.uk/pubs/files/dfidsynthesispaper.pdf.




47. Donald G. McNeil, Malaria Vaccine Proves Effective, N.Y. TiMES, October 15, 2004, at Al.
48. Id.
49. See Harvey Black, Samoa to Benefit from AIDS Dr7g (Oct. 1, 2004), available at http://www.biomed
central.com/news/20041001/02.
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on a no-cost basis or a nominal-cost basis.50 The agreement is also important for the rec-
ognition that it provides to the essential intellectual contribution of Samoan healers. 5'
C. INFLUENZA VACCINES
In late 2004, the United States faced an influenza vaccine crisis when British regulators
shut down the Chiron Corporation production facility in Liverpool, England, causing the
United States to lose approximately half of its expected influenza vaccine supply.5" Most
European countries, with the exception of Ireland, were only minimally affected by this
shutdown, because, unlike the United States, they typically rely on multiple manufacturers
to supply the needed vaccine." This shortage illustrates the need for national governments
to increase the number of sources from which they obtain their supply of influenza vaccine.
In addition, because there is no incentive for companies to produce excess vaccine, given
the frequent changes in the composition of the vaccine, this crisis also highlights the need
for a concerted effort among vaccine manufacturers, licensing agencies, and national gov-
ernments to ensure that a sufficient supply of influenza vaccine will always be available1 4
Experts believe that the crisis in the United States paled in comparison to the rationing
and emergency measures that would be required in a pandemic. While influenza annually
causes the death of approximately 36,000 people in the United States and one million
throughout the world, these figures represent only a fraction of the number of deaths
expected in a pandemic, which typically occurs every twenty to thirty years.5 6 In light of
the increasing signs that avian influenza can be transmitted from person to person, many
experts fear that a severe worldwide outbreak may be imminent." In response to such a
threat, on November 11, 2004, at an unprecedented emergency summit held in Geneva,
Switzerland, the WHO called for international cooperation among all influenza vaccine
producers and government health agencies to increase efforts aimed at eliminating the
escalating threat of an influenza pandemic.58
W. Stem Cell Research
Many members of the medical and scientific community are hopeful that research con-
ducted on embryonic and adult stem cells will yield treatments capable of curing serious
diseases and reversing the effects of debilitating conditions. However, this potential for
medical progress is fraught with legal and ethical considerations. Confronted with these
50. Id.
51. Id.
52. See Associated Press, Few Flu Vaccine Shortages in Europe (Oct. 21, 2004), available at http://www.
msnbc.msn.com/id/6300604/ [hereinafter Few Flu Vaccine Shortages]; see also David P. Fidler, Influenza Vaccine
Supply and International Law (Oct. 2004), available at http://www.asil.org/insights/2004/10/insightO41020.htm.
53. Few Flu Vaccine Shortages, supra note 52.
54. Id.




58. Ned Stafford, EU Underprepared for Flu (Nov. 2, 2004), available at http://www.biomedcentral.com/news/
20041102/01.
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competing considerations, countries have been vigorously attempting to strike a balance
between the promotion of scientific and medical research and the ethical issues related to
the sanctity of human life. What follows is an overview of some of the most significant legal
developments in this area that occurred during the past year.
A. INTERNATIONAL EFFORTS
In November 2004, after years of debate, the member states of the United Nations Gen-
eral Assembly legal committee considered two different proposals on the issue of human
cloning.19 The first, a proposal submitted by Costa Rica, contemplated a complete ban on
all forms of cloning.60 This proposal had the support of approximately sixty states, including
the United States. In contrast, a resolution put forth by Belgium endorsed a ban on human
reproductive cloning, while leaving to individual countries the discretion to address ther-
apeutic cloning, through a complete ban, a moratorium, or other legislative approach.6
This measure was supported by the United Kingdom, China, and Finland, among other
countries. 62 On the last day of the meeting, Italy submitted a new proposal in an attempt
to bridge the gap between the divided nations.63 This compromise envisages a non-binding
declaration aimed at encouraging member states to prohibit reproductive cloning and adopt
legislation promoting "human dignity."64 Based on the seemingly widespread support for
this new proposal, a working group met in February 2005 to finalize the text of such a
declaration.65
B. UNITED STATES AND CANADA
At the federal level, the United States has largely taken a "market-oriented approach to
stem cell research allowing virtually unfettered research in the private sector."6 Throughout
the 2004 presidential election campaign, President George W Bush reiterated his oppo-
sition to federal funding of embryonic stem cell research that would result in the destruction
of human embryos. 67 Instead, limited federal funds (approximately $25 million per year)
could be used for the continued research on existing stem cell lines. 6 Rather than imple-
menting national stem cell legislation, the United States federal government preferred to
leave the regulation of stem cell research to the individual states.
In November 2 004, California voters passed Proposition 71, a $3 billion measure, spread
over ten years, creating an Institute for Regenerative Medicine focused on embryonic stem









66. Kara L. Belew, Stem Cell Division: Abortion Law and Its Influence on the Adoption of Radically Different
Embyonic Stem Cell Legislation in the United States, the United Kingdom, and Germany, 39 Tex. Int'l Lj. 479, 499
(2004).
67. Dan Vergano, Stem-Cell Debate Another Division Between Bush, Kery, (Oct. 26, 2004), available at http://
www.usatoday.com/news/politicselections/nation/issues/2004-10-26-stem-cell-research-x.htm.
68. Id.
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cell research. 69 Other states, in response to the success of Proposition 71, are developing
funding measures in an attempt to halt an exodus of scientists to the West Coast. For
instance, New York introduced a proposal which would grant $1 billion in state funds to
the creation and development of a stem cell research program and institute. 70 If the required
governmental approvals are obtained, New Yorkers may vote on the proposal in an upcom-
ing election. 71 Similarly, in January 2005, legislators in Connecticut introduced a bill ad-
dressing the regulation and funding of stem cell research in the state." New Jersey also
introduced a proposal in 2004 under which state funds would be used to create and support
the New Jersey Institute for Stem Cell Research and to fund the NewJersey public/private
stem cell fund. 7"
On March 12, 2004, the Canadian Parliament passed An Act Respecting Assisted Human
Reproduction and Related Research on March 12, 2004. 74 While the law allows embryonic
stem cell research if certain conditions are met, it restricts the creation of embryos solely
for research purposes. 75 The legislation also establishes the Assisted Human Reproduction
Agency of Canada that is responsible for overseeing research using in vitro embryos.16
C. EUROPE AND THE EUROPEAN UNION
The French National Assembly approved a bioethics law" that permits embryonic stem
cell research provided that the principal aim of the research is the development of treat-
ments for serious diseases. Scientists are permitted to use spare unfertilized eggs obtained
from in vitro fertilization (IF) clinics for this research, on the condition that the donors
give their consent.7" The law prohibits creation of embryos solely for research purposes.
The legislation also provides for the establishment of a biomedicine agency in 2005 to
oversee issues related to stem cell research. 79
The Spanish government approved a Royal Decree clarifying the existing regulations
governing embryonic stem cell research. 0 Pursuant to the Royal Decree in 2004, scientists
are permitted to conduct research on spare embryos from IVF clinics that have been frozen
69. Alison McCook, An Eastern US Stem Cell Hub? (Jan. 20, 2005), available at http://www.biomedcentral.
comirnews/20050120/02/; see also, Ivan Oransky, California OKs Stem Cell Measure (Nov. 3, 2004), available at
http://www.biomedcentral.com/news/20041103/02.
70. McCook, supra note 69.
71. Id.
72. Id; see also, Steven Reinberg, Connecticut Eyes Stem Cell Law, THE SCIENrIsT (Jan. 6, 2005), available at
http://www.biomedcentral.com/news/20050106/01.
73. McCook, supra note 69.
74. Assisted Human Reproduction Act, ch.2, 2004 S.C. (Can.), available at http://laws.justice.gc.ca/en/A-13.4/
3289.html.
75. Id.
76. Doug Payne, Canada Passes Cloning Law (Mar. 16, 2004), available at http://www.biomedcentral.com/
news/20040316/03. See also Health Canada, Assisted Human Reproduction Legislation Receives Approval of Senate
(Mar. 11, 2004), available at http://www.hc-sc.gc.ca/english/media/releases/2004/2004_-1O.htm.
77. Law No. 2004-800 of Aug. 6, 2004, J.O no. 182, Aug. 7, 2004, p. 14040 (Fr.), available at http://www.
fivfrance.com/page-loi2004.html.
78. Id.
79. Jane Burgermeister, France Green Lights Stem Cells (Oct. 11, 2004), available at http://www.biomed
central.com/news/20041011/02.
80. Xavier Bosch, Spain Eases Embryo Research, THE ScIENTrST (Nov. 1, 2004), available at http://www.
biomedcentral.com/news/20041 101/01.
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for more than five years, if the donors have consented to the use of such embryos for
research purposes.8' In connection with this Royal Decree, Spain's Health Minister stated
that the government expects to approve a biomedical research law in 2005, that may include
provisions related to therapeutic cloning and will likely allow embryonic stem cell research
to be conducted on embryos that have been frozen for less than five years.8"
In 2004, the Swiss Parliament enacted legislation on embryonic stem cell research which
permits the extraction of, and research on, human embryos up to seven days old provided
that the donors have consented to the use of the spare embryo for research purposes. 3 The
Swiss law also provides that, under certain conditions, embryonic stem cells may be im-
ported from other countries for research purposes.8 4 Although the United Kingdom has
had legislation governing embryonic stem cell research in place since the Human Fertil-
isation and Embryology Act of 1990, on August 11, 2004, its Human Fertilisation and
Embryology Authority granted a team of scientists from the University of Newcastle in
Northern England permission to clone human embryos for exclusively scientific and medi-
cal purposes.85 If successful, this would be the first case of cloning human embryos in
Europe.86
The EU is also developing a framework to address the issues surrounding embryonic
stem cell research and human cloning. The same division among countries that manifested
itself at the United Nations has similarly affected the European countries in their attempt
to develop an acceptable framework for the EU. Nevertheless, some progress has been
made.87 The Treaty Establishing a Constitution for Europe (EU Constitution), expected to
enter into force on November 1, 2006, contains language setting out certain parameters
for the regulation of scientific and medical research."8 Article 11-63 of the EU Constitution
provides the following principles: (1) the free and informed consent of the person con-
cerned; (2) the prohibition of eugenic practices; (3) the prohibition of the commercialization
of the human body and its parts; and (4) the prohibition of the reproductive cloning of
human beings.89
81. Id. See also Steven Ertelt, Spain Advances Embryonic Stem Cell Research, Switzerland May Be Next (Oct. 30,
2004), available at http://66. 195.16.5 5/bio53 6.html.
82. Bosch, supra note 80.
83. Ned Stafford, Swiss Support Stem Cells (Nov. 29, 2004), available at http://www.biomedcentral.com/news/
20041129/02.
84. Id.
85. Human Fertilization and Embryology Act, 1990, c. 37 (Eng.).
86. Jean-Yves Nadeau, La Grande-Bretagne ouvre la voie au clonage d'embryons humainspourla recherche midicale
(Aug. 13, 2004), available at http://www.lemonde.fr.
87. See, e.g., Andrew Scott, EU Clarifies Stem Cell Rules (Nov. 5, 2003), available at http://www.biomed
central.com/news/20031105/06; Andrew Scott, Euro Parliament OKs Stem Cells (Nov. 20, 2003), available at
http://www.biomedcentral.com/news/20031120/08; Andrew Scott, EUin Stem CellLimbo (Dec. 4,2003), avail-
able at http://www.biomedcentral.com/news/20031204/05; Ned Stafford, Potocnik Backs ES Cell Research (Dec.
22, 2004), available at http://www.biomedcentral.com/news/20041222/02.
88. Treaty Establishing a Constitution for Europe, Dec. 16, 2004, Oj. (C 310) 1 (2004), available at http://
europa.eu.intleur-lex/JOHtmi.do?uri = OJ:C:2004:3 10:SOM:EN:HTML.
89. Id. at art. II-63(2).
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V. Right to Health
The newly adopted EU Constitution, although not yet in force, contains many provisions
with implications for health care in the EU,9° including the fundamental principle embodied
in Article 11-63 that all individuals have the right to "physical and mental integrity."9' Article
11-95 establishes that "[e]veryone has the right of access to preventive health care and the
right to benefit from medical treatment under the conditions established by national laws
and practices. A high level of human health protection shall be ensured in the definition
and implementation of all Union policies and activities." 92 In addition to these specific
health care provisions, the EU Constitution's provisions regarding the environment also
have implications for regional health efforts because of the environmental requirement to
protect human health.9" Finally, Article II1-278 of the EU Constitution provides that
"[a]ction by the [EU], which shall complement national policies, shall be directed towards
improving public health, preventing human illness and diseases, and obviating sources of
danger to physical and mental health."94 The EU Constitution specifies that such actions
shall include "the fight against the major health scourges, by promoting research into their
causes, their transmission and their prevention, as well as health information and education;
[and] monitoring, early warning and combating serious cross-border threats to health.""
VI. WHO Framework Convention on Tobacco Control
In November 2004, the United Nations Treaty Section received the fortieth ratification
for the WHO Framework Convention on Tobacco Control (WHO FCTC) and as a result
the WHO FCTC entered into force on February 28, 2005.96 The WHO FCTC, which
was adopted unanimously by the WHO's 192 member states in May 2003, is the first in-
ternational legal instrument designed to reduce tobacco-related disease and deaths.9 Cur-
rently, over 1.2 billion people in the world smoke9s and approximately 4.9 million tobacco-
related deaths occur each year.- This latter figure is higher than the annual number of
90. Health-related provisions in the EU Constitution include Articles 11-61 (Human integrity), 1-62 (Right
to life), 11-63 (Right to the integrity of the person), 11-64 (Prohibition of torture and inhuman or degrading
treatment or punishment), 11-65 (Prohibition of slavery and forced labour), 11-66 (Right to liberty and security),
11-68 (Respect for private and family life), 11-68 (Protection of personal data), 11-69 (Right to marry and right
to found a family), 11-74 (Right to education), 11-80 (Equality before the law), 11-81 (Non-discrimination),
11-82 (Cultural, religious and linguistic diversity), 11-83 (Equality between men and women), 11-84 (The rights
of the child), 11-85 (The rights of the elderly), 11-86 (Integration of persons with disabilities), 11-92 (Prohibition
of child labour and protection of young people at work), 11-93 (Family and professional life), 11-94, (Social
security and social assistance), 11-95 (Health care), 11-97 (Environmental protection), and 11-98 (Consumer
protection).
91. Treaty Establishing a Constitution for Europe, supra note 88, at art. 1-63(1).
92. Id. at art. 11-95.
93. Id. at art. I-233(1) ("Union policy on the environment shall contribute to ... protecting human
health").
94. Id. at art. I1-278(1).
95. Id.
96. World Health Organization, WHO Tobacco Treaty Set to Become Law, Making Global Public Health History,
(Dec. 1, 2004) available at http://www.who.int/mediacentre/news/releases/2004/pr89/en/.
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deaths related to AIDS, legal drugs, illegal drugs, road accidents, murder and suicide com-
bined. 100 The impact of tobacco on the physical health of a population has significant im-
plications for governments, businesses, and the environment. 1 1 The resulting health, social,
and economic costs provided the impetus for adoption of the WHO FCTC.
The WHO FCTC establishes a comprehensive framework for addressing the risks of
exposure to and use of tobacco. States parties to the WHO FCTC must "adopt and im-
plement effective legislative, executive, administrative and/or other measures and cooperate,
as appropriate, with other [countries] in developing appropriate policies for preventing and
reducing tobacco consumption, nicotine addiction and exposure to tobacco smoke."' °2 In
particular, the WHO FCTC requires that states (1) implement restrictions on tobacco
advertising, sponsorship, and promotion; (2) establish new packaging and labelling of to-
bacco products; (3) establish clean indoor air controls; (4) implement or revise legislation
to eliminate tobacco smuggling; and (5) prohibit the sale of tobacco products to minors. 0 s
As of April 7, 2005, 168 countries had signed the WHO FCTC, including the United
States, but only sixty-one countries had ratified or acceded to the WHO FCTC.'04 The
United States has not yet ratified the WHO FCTC. °5
VII. Bioterrorism
Bioterrorism, now more than ever, is a significant threat to the health and safety of the
world's population, and during 2004 cooperation at the international level continued to be
a priority for many countries. In particular, at the G8 Summit held in June 2004, members
reaffirmed their commitment to
concrete national and international steps to: expand or, where necessary, initiate new biosurv-
eillance capabilities to detect bioterror attacks against humans, animals, and crops; improve
[their] prevention and response capabilities; increase protection of the global food supply; and
respond to, investigate, and mitigate the effects of alleged uses of biological weapons or sus-
picious outbreaks of disease. In this context, [they] seek concrete realization of [their] com-
mitments at the fifth Review Conference of the [Biological and Toxin Weapons Convention.16
G8 members recognized the importance of the 1972 Biological and Toxin Weapons Con-
vention and the 1993 Chemical Weapons Convention as critical tools against the prolif-
100. World Health Organization, Building Blocks for Tobacco Control A Handbook 6 (2004), available at http://
www.who.int/tobacco/resources/publications/general/en/HANDBOOK%20Lowres%20with%20cover.pdf.
101. Id. at 11-12 (noting the costs to governments and employers of accommodating the sick, including
increased expenditures on health care, the financial cost of absenteeism from work, and also environmental
degradation as a result of the tobacco industry).
102. WHO Framework Convention on Tobacco Control, WHA Res. 56. 1, World Health Assembly, 56th
Ass., 4th plea. mtg., Agenda Item 13, WHO Doc. A56.VR/4, art. 5(2)(b), available at http://www.who.int/gb/
ebwha/pdf-files/WHA56/ea56rl .pdf.
103. WHO Framework Convention on Tobacco Control, WHA Res. 56. 1, World Health Assembly, 56th
Ass., 4th plea. mtg., Agenda Item 13, WHO Doc. A56.VR/4, available at http://www.who.int/gb/ebwha/pdf-
files/WHA56/ea56rl .pdf.
104. World Health Organization, Updated Status of the WHO Framework Convention on Tobacco Control (Feb.
27, 2005), available at http://www.who.int/tobacco/framework/countrylist/en/.
105. Id.
106. Press Release, Office of the White House Press Secretary, G8 Action Plan on Nonproliferation
(June 9, 2004), available at http://www.whitehouse.gov/news/releases/2004/06/20040609-28.html.
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eration of biological weapons, and they urged all nations who had not yet done so to
promptly implement their provisions.107
In 2004, the WHO also revised its 1970 publication Health Aspects of Biological and Chem-
ical Weapons'08 and issued the Public Health Response to Biological and Chemical Weapons: WHO
Guidance.109 The new version provides information to assist nations in preparing for and
responding to bioterrorism caused by the use of biological and chemical agents. 110
VIII. Tsunami and Other International Disasters
As of late-January 2005, reports indicated that more than 212,000 people perished as a
result of the tsunami that struck in the Indian Ocean on December 26, 2004.111 While the
international outpouring of generosity, including donations from governments, organiza-
tions and individuals, was rapid and widespread, this natural disaster has spurred the inter-
national community to consider again the need for an international framework to coordi-
nate a response to global events and to redefine the role that international law should play
in satisfying this need. A body of international law, including several treaties,' 12 has already
been developed to address man-made disasters of global proportions, and to provide guid-
ance to help nations "prevent, prepare for, and respond to technological disasters with
potential transboundary effects.'" Unlike man-made disasters, natural disasters cannot be
prevented entirely through international cooperation. Rather, in such circumstances, the
role of the international community is limited generally to the development of preparedness
strategies and the coordination of relief. 14
The International Disaster Response Law (IDRL) project, sponsored in 2000 by the
International Federation of the Red Cross and Red Crescent Societies, concluded that the
effectiveness and level of coordination of international responses to global disasters vary
greatly from region to region."' Such disparity was most recently exemplified by the re-
sponse to the Indian Ocean tsunami when the IDRL project noted the difficulty of dealing
with twelve different governments and with its own customs regulations." 6 While the prin-
ciple aim of the IDRL project is to identify how the response to international disasters
could be improved through changes in national and international law,"' the World Con-
107. Id.
108. World Health Organization, Health Aspects of Chemical and Biological Weapons: Report of a WHO Group
of Consultants (1970), available at http://www.who.int/csr/delibepidemics/biochem lstenglish/en/.
109. World Health Organization, Public Health Response to Biological and Chemical Weapons: WHO Guidance
(2004), available at http://www.who.int/csr/delibepidemics/biochemguide/en/index.html.
110. Id.
11. Tsunami deaths soar past 212,000 (Jan 19, 2005), available at http://www.cnn.com/20O5/WORLD/
asiapcf/01/1 9/asia.tsunami/.
112. For example, following the Chernobyl nuclear disaster, several treaties addressing nuclear energy fa-
cilities were concluded.
113. David P. Fidler, The Indian Ocean Tsunami and International Law (Jan. 2005), available at http://www.
asil.org/insights/2005/01/insightO5Ol I 8.htn.
114. Id.
115. International Federation of Red Cross and Red Crescent Societies, IDRL Legal Research: Research into
Existing IDRL Treaties (March 2003), available at http://www.ifrc.org.
116. Press Release, International Federation of Red Cross and Red Crescent Societies, Tsunami Operation
Offers Reminder of Need for Disaster Reduction Measures (Jan. 12, 2005), available at http://www.ifrc.org/
docs/News/pr05/0605.asp.
117. See Fidler, supra note 113.
SUMMER 2005
516 THE INTERNATIONAL LAWYER
ference on Disaster Reduction, sponsored by the United Nations, in Kobe, Japan in Jan-
uary 2005, considered whether the global impact of most natural disasters requires the
further development of international law through multilateral conventions.- 0 Although the
World Conference was scheduled prior to the occurrence of the tsunami, the tsunami was
a prominent topic of discussion. The World Conference issued a Common Statement em-
phasizing the need for a coordinated international response to disasters and the importance
of establishing tsunami early warning systems in the Indian Ocean region.9 It also adopted
the Hyogo Declaration 20 and the Hyogo Framework for Action, 2005-2015,121 which rec-
ognize the importance of disaster reduction strategies, particularly through the use of in-
ternational law, for achieving global sustainable development.
IX. Conclusion
All of the developments described in this article reflect the growing recognition of the
important role of law and the legal community in international health. Multilateral and
bilateral arrangements enable governments to coordinate responses to public health con-
cerns. In addition, legislation provides incentives for healthcare organizations and profes-
sionals to promote and protect the public's health, and it helps alleviate disparities in access
to and delivery of quality health care.'22 The American Bar Association's House of Delegates
adopted a recommendation in 2004 "urg[ing] its members and lawyers throughout the
United States to improve their knowledge of public health law... [and] to become involved
in assessing and improving the public health legal preparedness of the communities in which
they live and work and ensuring that public health measures are protective of civil and
constitutional rights."'23 Contributions from all sectors of society, including lawyers and
health care professionals, are vital to the development of international health law and can
help ensure that all countries develop appropriate responses to the health care needs of
their population.
118. See World Conference on Disaster Reduction, Brief history of the WCDR Process: Road to the WDCR,
available at http://www.unisdr.org/wcdr/ (last visited May 19, 2005).
119. United Nations, World Conference on Disaster Reduction, Common Statement of the Special Session on
the Indian Ocean Disaster: Risk Reduction for a Safer Future (Mar. 16, 2005) (Extract from the final report of the
World Conference on Disaster Reduction (A/CONF.206/6)), available at http://www.unisdr.org/wcdr/intergover/
official-doc/L-docs/special-session-indian-ocean.pdf.
120. United Nations, World Conference on Disaster Reduction, Hyogo Declaration (Mar. 16, 2005) (Extract
from the final report of the World Conference on Disaster Reduction (A/CONF.206/6)), available at http:/
www.unisdr.org/wcdr/intergover/official-doc/L-docs/Hyogo-declaration-english.pdf.
121. United Nations, World Conference on Disaster Reduction, Hyogo Framework ofAction, 2005-2015(Mar.
16, 2005) (Extract from the final report of the World Conference on Disaster Reduction (AICONF.206/6)),
available at http://www.unisdr.org/wcdr/intergover/official-dc/L-docs/Hyogo-framework-for-action-english.
pdf.
122. See George A. Mensah et al., Law as a Tool for Preventing Chronic Diseases: Expanding the Spectrum of
Effective Public Health Strategies, 1 PREVENTING CHRONIC DISEASE 1 (Jan. 2004), available at http://www.cdc.gov/
pcd/issues/2004/jan/pdf/03_0033 .pdf.
123. American Bar Association, Report: Public Health Law Awareness Among American BarAssociation Members
(August 2004) (adopted by the American Bar Association House of Delegates), available at http.J/www.abanet.org/
leadership/2004/annual/dailyjournal/ 02 .doc.
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